Literature DB >> 10666243

Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region.

B Labrosse1, C Treboute, M Alizon.   

Abstract

The triterpene RPR103611 is an efficient inhibitor of membrane fusion mediated by the envelope proteins (Env, gp120-gp41) of CXCR4-dependent (X4) human immunodeficiency virus type 1 (HIV-1) strains, such as HIV-1(LAI) (LAI). Other X4 strains, such as HIV-1(NDK) (NDK), and CCR5-dependent (R5) HIV-1 strains, such as HIV-1(ADA) (ADA), were totally resistant to RPR103611. Analysis of chimeric LAI-NDK Env proteins identified a fragment of the NDK gp41 ectodomain determining drug resistance. A single difference at position 91, leucine in LAI and histidine in NDK, apparently accounted for their sensitivity or resistance to RPR103611. We had previously identified a mutation of isoleucine 84 to serine in a drug escape LAI variant. Both I84 and L91 are located in the "loop region" of gp41 separating the proximal and distal helix domains. Nonpolar residues in this region therefore appear to be important for the antiviral activity of RPR103611 and are possibly part of its target. However, another mechanism had to be envisaged to explain the drug resistance of ADA, since its gp41 loop region was almost identical to that of LAI. Fusion mediated by chimeric Env consisting of LAI gp120 and ADA gp41, or the reciprocal construct, was fully blocked by RPR103611. The gp120-gp41 complex of R5 strains is stable, relative to that of X4 strains, and this stability could play a role in their drug resistance. Indeed, when the postbinding steps of ADA infection were performed under mildly acidic conditions (pH 6.5 or 6.0), a treatment expected to favor dissociation of gp120, we achieved almost complete neutralization by RPR103611. The drug resistance of NDK was partially overcome by preincubating virus with soluble CD4, a gp120 ligand inducing conformational changes in the Env complex. The antiviral efficacy of RPR103611 therefore depends on the sequence of the gp41 loop and the stability of the gp120-gp41 complex, which could limit the accessibility of this target.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10666243      PMCID: PMC111694          DOI: 10.1128/jvi.74.5.2142-2150.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

Authors:  J M Kilby; S Hopkins; T M Venetta; B DiMassimo; G A Cloud; J Y Lee; L Alldredge; E Hunter; D Lambert; D Bolognesi; T Matthews; M R Johnson; M A Nowak; G M Shaw; M S Saag
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

Review 2.  Chemokine receptors: keys to AIDS pathogenesis?

Authors:  D R Littman
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

Review 3.  Chemokines and coreceptors in HIV/SIV-host interactions.

Authors:  T L Hoffman; R W Doms
Journal:  AIDS       Date:  1998       Impact factor: 4.177

Review 4.  Coiled coils in both intracellular vesicle and viral membrane fusion.

Authors:  J J Skehel; D C Wiley
Journal:  Cell       Date:  1998-12-23       Impact factor: 41.582

5.  Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41.

Authors:  M Caffrey; M Cai; J Kaufman; S J Stahl; P T Wingfield; D G Covell; A M Gronenborn; G M Clore
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

Review 6.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

Authors:  E A Berger; P M Murphy; J M Farber
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

7.  Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1.

Authors:  R Merat; H Raoul; T Leste-Lasserre; P Sonigo; G Pancino
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

8.  Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41.

Authors:  I Muñoz-Barroso; S Durell; K Sakaguchi; E Appella; R Blumenthal
Journal:  J Cell Biol       Date:  1998-01-26       Impact factor: 10.539

9.  Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100.

Authors:  B Labrosse; A Brelot; N Heveker; N Sol; D Schols; E De Clercq; M Alizon
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

Review 10.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

Authors:  R Wyatt; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

View more
  14 in total

1.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Genetically Intact but Functionally Impaired HIV-1 Env Glycoproteins in the T-Cell Reservoir.

Authors:  Anne de Verneuil; Julie Migraine; Fabrizio Mammano; Jean-Michel Molina; Sébastien Gallien; Hugo Mouquet; Allan J Hance; François Clavel; Jacques Dutrieux
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

4.  A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.

Authors:  Edward J Murray; Daniel P Leaman; Nishant Pawa; Hannah Perkins; Chris Pickford; Manos Perros; Michael B Zwick; Scott L Butler
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

5.  Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564.

Authors:  S L Holz-Smith; I C Sun; L Jin; T J Matthews; K H Lee; C H Chen
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

6.  Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.

Authors:  Weihong Lai; Li Huang; Phong Ho; Zhijun Li; David Montefiori; Chin-Ho Chen
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

7.  Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents.

Authors:  Keduo Qian; Donglei Yu; Chin-Ho Chen; Li Huang; Susan L Morris-Natschke; Theodore J Nitz; Karl Salzwedel; Mary Reddick; Graham P Allaway; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

Review 8.  HIV entry inhibitors and their potential in HIV therapy.

Authors:  Keduo Qian; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2009-03       Impact factor: 12.944

9.  Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.

Authors:  Séverine Bär; Marc Alizon
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

Review 10.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.